BofA Cuts Doximity Price Target to $70, Keeps Buy Rating Amid Softer Pharma Ad Trends
BofA Securities reduced its price target for Doximity Inc. to $70 from $82 while retaining a Buy rating, citing softer pharmaceutical advertising trends and peer multiple compression. The firm still forecasts mid-teens revenue growth in fiscal 2027 supported by new product module adoption and shifts in ad allocation, and other major brokers continu…